THURSDAY, Feb. 11, 2021 (HealthDay News) — Individuals with overweight or obesity receiving once-weekly subcutaneous semaglutide plus lifestyle intervention achieved sustained, clinically relevant reductions in body weight, according to a study published online Feb. 10 in the New England Journal of Medicine. John P. H. Wilding, D.M., from the University of Liverpool in the United...